Tech Company Financing Transactions
Matter Bio Funding Round
On 5/29/2024, Matter Bio secured $7 million in Seed funding from LifeSpan Vision Ventures, National Institute of Environmental Health Sciences and National Institutes of Health.
Transaction Overview
Company Name
Announced On
5/29/2024
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to conduct further research into the information theory of aging at a genomic level, file an IND, and start a Phase 1/2a clinical trial in solid cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
New York, NY Undisclosed
USA
New York, NY Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Matter Bioworks is a longevity holding company focused on preserving genome integrity. As we age, our genome is constantly being damaged by exogenous and endogenous sources. Occasionally errors are missed and incorporated into the DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chris Bradley
Co-Founder
Sam Sharifi
Browse more venture capital transactions:
Prev: 5/29/2024: Old Well Labs venture capital transaction
Next: 5/29/2024: Slingshot Media venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs